Immunohistochemical assay for detection of CD3 and CD16

Patent metadata

Field	Value
Publication number	US-9689875-B2
Application number	US-201414914345-A
Country	US
Kind code	B2
Filing date	Aug 21, 2014
Priority date	Aug 28, 2013
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present application provides methods and systems for detecting both CD3 and CD16 in a sample using immunohistochemical methods, for example when the primary antibodies for CD3 and CD16 are from the same species (e.g., both rabbit antibodies). Methods to denature and block the first primary antibody contacted with the sample are provided.

First claim

The invention claimed is:

1. A method of detecting CD3 protein and CD16 protein in a sample, comprising:
contacting the sample with a buffer comprising Tris, a preservative, wherein the pH of the buffer is about 8-9;
contacting the sample with a CD3 antibody;
contacting the sample with a labeled secondary antibody to permit detection of the CD3 antibody;
denaturing the sample by incubating the sample at 80° C.-100° C. for at least 5 minutes;
contacting the sample with a blocking antibody;
contacting the sample with the buffer;
contacting the sample with a CD16 antibody;
contacting the sample with a labeled secondary antibody to permit detection of the CD16 antibody; and
determining that CD3 protein is present in the sample if the labeled secondary antibody to permit detection of the CD3 antibody is detected, determining that CD16 protein is present in the sample if the labeled secondary antibody to permit detection of the CD16 antibody is detected, or combinations thereof.

2. The method of claim 1 , wherein the sample is contacted with the buffer for at least 30 minutes prior to contacting the sample with the CD3 antibody.

3. The method of claim 1 , wherein the sample is contacted with the buffer for 40 minutes prior to contacting the sample with the CD3 antibody.

4. The method of claim 1 , wherein the sample is contacted with the CD3 antibody for at least 5 minutes at 37° C.

5. The method of claim 1 , wherein the sample is contacted with the CD3 antibody for 8 minutes at 37° C.

6. The method of claim 1 , wherein the CD3 antibody is rabbit monoclonal antibody clone 2GV6 (VMSI, Catalog No. 790-4341).

7. The method of claim 1 , wherein the labeled secondary antibody that permits detection of the CD3 antibody comprises an anti-rabbit-HQ conjugate or an anti-mouse-HQ conjugate and an anti-HQ-HRP antibody, and the method further comprises contacting the sample with hydrogen peroxide in the presence of diaminobenzidine (DAB) and copper sulfate.

8. The method of claim 1 , wherein the denaturing the sample comprises incubating the sample at 95° C. for at least 8 minutes.

9. The method of claim 1 , wherein the blocking antibody comprises a chicken anti-rabbit antibody if the CD3 antibody is a rabbit antibody.

10. The method of claim 1 , wherein the method further comprises contacting the sample with a reaction buffer comprising Tris for at least 20 minutes to remove residual blocking antibody.

11. The method of claim 1 , wherein the CD16 antibody is rabbit monoclonal antibody clone J224H2L1.

12. The method of claim 1 , wherein the labeled secondary antibody that permits detection of the CD16 antibody comprises an anti-rabbit-AP multimer or an anti-mouse-AP multimer, and the method further comprises contacting the sample with napthol in the presence of alkaline phosphatase enhancer and fast red.

13. The method of claim 1 , wherein the sample is a formalin fixed, paraffin embedded (FFPE) sample.

14. The method of claim 1 , wherein the sample is a cancer sample.

15. The method of claim 1 , wherein the CD3 antibody and the CD16 antibody are from the same host species.

16. The method of claim 1 , further comprising scoring the presence of CD3 protein and CD16 protein.

17. The method of claim 16 , wherein the sample comprises a tumor sample, and scoring the presence of CD3 protein and CD16 protein comprises:
a) determining an absolute number of cells staining with the CD3 antibody in the sample using a 5×5 ocular grid with an area of 0.25 square millimeter,
determining an absolute number of cells staining with the CD16 antibody in the sample using a 5×5 ocular grid with an area of 0.25 square millimeter,
extrapolating the absolute number of cells staining with the CD3 antibody to a number of cells in a 1 square millimeter region, and
extrapolating the absolute number of cells staining with the CD16 antibody to a number of cells in a 1 square millimeter region,
thereby generating a score of CD3 protein and CD16 protein;
b) determining the area of staining with the CD3 antibody within the intratumoral and contiguous peri-tumoral stroma of the sample,
determining the area of staining with the CD16 antibody within the intratumoral and contiguous peri-tumoral stroma of the sample,
dividing the area of staining with the CD3 antibody in the intratumoral and contiguous peri-tumoral stroma by the area of total stroma, thereby generating a score of CD3 protein for the stroma, and
dividing the area of staining with the CD16 antibody in the intratumoral and contiguous peri-tumoral stroma by the area of total stroma, thereby generating a score of CD16 protein for the stroma;
c) a combination of a) and b).

18. The method of claim 17 , wherein 1 to 15 randomly selected regions of the sample containing the tumor are selected for scoring.

19. The method of claim 17 , wherein the region of the tumor consists of tumor cells only, stroma only or tumor and stroma.

20. The method of claim 1 , wherein the method further comprises producing an output of the number of CD3 cells and CD16 cells.

21. The method of claim 1 , wherein one or more of the steps are performed by a suitably programmed computer.

22. The method of claim 1 , wherein the sample comprises a tumor sample and the method is a method of determining the likelihood that the tumor will respond to an anti-EGFR targeted therapeutic agent, and the method further comprises
determining that the tumor will respond to the anti-EGFR targeted therapeutic agent if the sample has an increased CD3 and/or CD16 score relative to a normal sample, or
determining that the tumor will not respond to the anti-EGFR targeted therapeutic agent if the sample has a similar or decreased CD3 and/or CD16 score relative to a normal sample.

23. The method of claim 1 , wherein the sample comprises a tumor sample and the method is a method of determining whether the tumor responded to an anti-EGFR targeted therapeutic agent, and the method further comprises
determining that the tumor did not respond to the anti-EGFR targeted therapeutic agent if the sample has an increased CD3 and/or CD16 score relative to a normal sample, or
determining that the tumor responded to the anti-EGFR targeted therapeutic agent if the sample has a similar or decreased CD3 and/or CD16 score relative to a normal sample.

24. The method of claim 22 , wherein the anti-EGFR targeted therapeutic agent comprises GA201.

25. One or more computer-readable storage media comprising computer-executable instructions causing a computer to perform the method of claim 1 .

26. A system comprising:
a slide holder comprising a plurality of slides, wherein the slides comprise tissue samples;
a buffer dispenser configured to contact slides in the slide holder with the buffer;
a CD3 antibody dispenser configured to contact slides in the slide holder with the CD3 antibody;
a CD3 antibody secondary dispenser configured to contact slides in the slide holder with the CD3 secondary antibody;
a denaturer configured to denature the CD3 antibody on the slides;
a blocking antibody secondary dispenser configured to contact slides in the slide holder with the blocking antibody;
a CD16 antibody dispenser configured to contact slides in the slide holder with the CD3 antibody;
a CD16 antibody secondary dispenser configured to contact slides in the slide holder with the CD16 secondary antibody; and
an imager and/or a detecto

Assignees

• Ventana Med Syst Inc

Inventors

• Smith Jacquelyn
• Hnatyszyn Harry James
• Olson Erik
• Theiss Noah
• Yates Alton
• Kaldjian Eric
• Vennapusa Bharathi

Classifications

• G01N33/5759 Primary

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N2333/70596

  Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 · CPC title

• G01N2333/70535

  Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F) · CPC title

• G01N33/57492 Primary

  Physics · mapped topic

• G01N2333/7051

  T-cell receptor (TcR)-CD3 complex · CPC title